Big outbreaks of Hand Foot and Mouth Disease (HFMD) have been occuring in China since 2008. HFMD became the No. 1 reported infectious disease in China in 2011, more cases than those of hepatitis caused by all hepatitis viruses combined.
At 2012’s World Vaccine Congress Asia, Shuo Shen, Chief Scientific Officer at Wuhan Institute of Biological Products at China National Biotec Group (CNBG) – the largest biotech company in China, delivered his presentation on “Development of the ânext' generation of enterovirus vaccines against Hand, Foot and Mouth Disease (HFMD)”. Download the presentation here.
This year, 17 – 20 June in Singapore, the 7th World Vaccine Congress Asia 2013 will address the challenges of conducting clinical studies for HFMD vaccine with Fengcai Zhu, Deputy Director at Jiangsu Provincial Center for Disease Prevention and Control. Zhu partners Sinovac and CNBG for the phase III clinical trial for the EV71 vaccine in prevention of HFMD.